Search alternatives:
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
marker decrease » marked decrease (Expand Search), larger decrease (Expand Search), marked increase (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
e decrease » we decrease (Expand Search), _ decrease (Expand Search), a decrease (Expand Search)
a largest » _ largest (Expand Search), a large (Expand Search), a latest (Expand Search)
a marker » _ marker (Expand Search), _ markers (Expand Search)
largest decrease » larger decrease (Expand Search), marked decrease (Expand Search)
marker decrease » marked decrease (Expand Search), larger decrease (Expand Search), marked increase (Expand Search)
nn decrease » _ decrease (Expand Search), a decrease (Expand Search), mean decrease (Expand Search)
e decrease » we decrease (Expand Search), _ decrease (Expand Search), a decrease (Expand Search)
a largest » _ largest (Expand Search), a large (Expand Search), a latest (Expand Search)
a marker » _ marker (Expand Search), _ markers (Expand Search)
-
1
-
2
-
3
Effects of GJE extract treatment decreased expression of NF-kB p65.
Published 2025“…<p>Control (A), NF (B), NF + Low dose GJE (C), and NF+High dose GJE (D) groups using immunohistochemistry (40X magnification). …”
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
Effects of CGA on renal biochemical markers.
Published 2025“…<div><p>Diabetic nephropathy (DN) is the single largest cause of end-stage renal disease (ESRD). Inflammation reaction mediated by NLRP3 inflammasome and Nrf2-related oxidative stress have been considered to play a very important role in the progress of diabetic nephropathy (DN). …”
-
12
-
13
Evogliptin attenuates the phenotypic switch of VSMCs during CER treatment by decreasing the osteogenesis-associated genes <i>in-vitro.</i>
Published 2025“…Bar graphs depicted EVO increased mRNA expression of (D) SM22α and decreased (E) RUNX2 in CER treated P<sub>i</sub>-induced VSMCs. …”
-
14
-
15
-
16
-
17
-
18
-
19
Evogliptin attenuates the pyroptotic cell death of VSMCs during CER treatment by decreasing the pyroptotic-associated genes and GSDM-D cleavage efficiency <i>in-vitro.</i>
Published 2025“…Summarized bar graphs showed EVO significantly decreased mRNA expression of pyroptotic markers (B) NLRP3 and (C) GSDM-D in CER treated P<sub>i</sub>-induced VSMCs. …”
-
20